Want to see CH:ADXN full AI Analyst Report?
ADXN Stock Chart & Stats
CHF0.02
<CHF0.01(10.00%)
―
--
Day’s Range― - ―
52-Week RangeCHF0.02 - CHF0.07
Previous CloseN/A
VolumeN/A
Average Volume (3M)757.72K
Market Cap
CHF2.45M
Enterprise ValueCHF4.26M
Total Cash (Recent Filing)CHF767.33K
Total Debt (Recent Filing)CHF77.50K
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding218,654,500
10 Day Avg. Volume517,477
30 Day Avg. Volume757,719
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.30
Price to Sales (P/S)35.91
P/FCF Ratio-2.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)CHF1.50M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage reduces fixed financial obligations and near-term solvency pressure while the company funds clinical development. This gives Addex more flexibility to pursue partnerships, milestones, and pipeline decisions without the additional constraint of substantial debt service.
Extended Funding RunwayThe additional financing and stated runway provide more time to advance multiple clinical and preclinical programs, pursue partnerships, and reach value-relevant milestones. This can reduce immediate financing disruption, although continued development still depends on disciplined cash management.
Expanded Proprietary PipelineRegaining full rights restores strategic control over a broad GABAB PAM portfolio and allows Addex to develop assets internally, partner them, or pursue different indications. Combined with advancing candidates, this increases optionality for future monetization and portfolio prioritization.
Bears Say
Deep, Persistent UnprofitabilitySevere and continuing losses show that the current clinical-stage model has not yet produced economically sustainable earnings. Without approved products or dependable collaboration income, ongoing deficits can erode equity and increase reliance on future financing or strategic transactions.
Negative Cash GenerationPersistent cash consumption means Addex cannot currently fund its operations and pipeline solely from internally generated resources. This places greater importance on external capital, partnerships, or asset monetization and can force development sequencing around available funding rather than scientific priorities.
Funding Required For Pipeline AdvancementThe need to secure financing before starting planned chronic cough studies creates a direct execution constraint on pipeline progress. Delayed funding could postpone clinical entry, extend the period before potential milestone creation, and increase dependence on investors or partners to advance additional programs.
Addex Therapeutics News
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was CHF0.02 and its highest was CHF0.07 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is CHF2.45M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Nov 09, 2026 which is in 18 days.
How were Addex Therapeutics’s earnings last quarter?
Addex Therapeutics released its earnings results on Sep 28, 2026. The company reported -CHF0.01 earnings per share for the quarter.
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Undervalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 218,654,500 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Addex Therapeutics reported an EPS of -CHF0.01 in its last earnings report. Following the earnings report the stock price went down -12.5%.
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in CH:ADXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.